EFFICACY OF MECAPEGFILGRASTIM IN PREVENTING CHEMOTHERAPY-INDUCED NEUTROPENIA IN ATHLETES UNDERGOING CANCER TREATMENT: A CLINICAL STUDY

Abstract

Objective: This study aimed to evaluate the prophylactic use of thiopefilgrastim for managing chemotherapy-induced neutropenia, particularly focusing on its application in athletic patients undergoing cancer treatment. Methods: We conducted a retrospective analysis of 456 athletic patients treated at Jiading District Central Hospital from December 2018 to June 2022. These patients were undergoing chemotherapy for malignant tumors and utilized either mecapegfilgrastim or recombinant human granulocyte stimulating factor (rhG-CSF) to counteract chemotherapy-induced bone marrow suppression. Patients were grouped into the mecapegfilgrastim group (experimental group) and the rhG-CSF group (control group), based on the type of white blood cell-enhancing drugs used. Data on treatment outcomes, bone marrow suppression, febrile neutropenia, and adverse reactions were collected and analyzed. Results: Of the patients studied, 266 were treated with mecapegfilgrastim, while 190 received rhG-CSF. Significant differences were observed between the two groups in treatment efficacy, bone marrow suppression, febrile neutropenia, and adverse reactions. Conclusion: Thiopefilgrastim was found to effectively reduce the incidence of neutropenia in athletes undergoing tumor chemotherapy, showing superior effectiveness and safety compared to rhG-CSF. This suggests its viability as a safer and more efficacious option for athletic patients in maintaining physical health during cancer treatment.